MissionSupport basic science, translational and clinical research through a competitive grants program that advances medical knowledge in the pathogenesis, treatment and prevention of infections.
BackgroundPrevious ASPIRE programs have supported laboratory based projects (in vitro, in vivo) evaluating MRSA pathogenesis and host response. In contrast, the focus of ASPIRE 2011 is to evaluate anti-infective therapies including linezolid in defined patient populations with specific infections through submission of innovative research proposals.
Young InvestigatorsThe ASPIRE Program demonstrates Pfizer’s commitment to supporting promising young investigators with an interest in advancing knowledge in defined areas including infectious diseases and antibacterial research.
Request for ProposalsPfizer invites academic leaders to nominate junior faculty to apply for the 2011 ASPIRE Young Investigator Awards in Antibacterial Research through submission of innovative research proposals that evaluate the impact of anti-infective therapies including linezolid in defined patient populations with specific infection types.
2011 Research TopicMRSA Clinical Research in Specific Patient Populations and Infection Types
Although considerable clinical trial data exists for linezolid, knowledge gaps remain in various patient populations noted below. It is hoped the resulting data will lead to a better understanding of the safety and efficacy of linezolid to enhance the clinical care of patients with bacterial infections.
Research RequirementsAn applicant should have a strong academic career interest within the areas of focus and should consider the following components when developing their research proposals:
A. Clinical evaluations of anti-infective therapies including linezolid within the following infection types including new or recurrent infections due to MRSA
- Nosocomial pneumonia (e.g. HAP, VAP, HCAP)
- Complicated skin and soft tissue infection (e.g. surgical site infection, wound, infected ulcers, abscesses, complicated cellulitis)
- Diabetic foot infection without osteomyelitis
- Renal insufficiency
- Pulmonary comorbidities
- Critically ill
- Morbidly obese
- Vascular disease
Research ExpectationsWithin the specified patient populations with infection types of interest, investigators are expected to:
- Generate exploratory clinical data in patients receiving linezolid to better understand disease pathogenesis, risk factors, host response and treatment outcomes
- Be able to complete the research in 12 months
- Present and/or publish the results of the study
Available AwardsPfizer is funding research awards up to a maximum of $100,000 USD/CDN each for one year to conduct clinical research generating data that will lead to a better understanding of the safety and efficacy of linezolid to enhance the clinical care of patients with bacterial infections.
Deadline for Application
- Applications must be received by 11:59pm EST on June 30, 2011.
- Addenda, supplemental materials, changes, or updates will not be accepted after the deadline.